met need for medical weight Novo Nordisk ® countries Global reimbursement status 58 countries 70% access in commercial channel, but due to employer opt-in, effective access is around 20% Reimbursement is predominantly out-of-pocket NICE has recommended Saxenda ® for use by NHS in select patient populations ~60% coverage by private insurance, 20% of which includes restricted/unrestricted coverage Saxenda ® reimbursed April 2020 in selected patient groups tional Institute for Health and Care Excellence; NHS: National Health Service
Download PDF file